Don’t just invest—dominate with Tech Contrarians' realized return on closed positions of 65.8% since inception. You’ll get exclusive insights into high-focus stocks, curated watchlists, one-on-one portfolio consultations, and everything from live portfolio tracking to earnings updates on 50+ companies. Subscribe today.Hims & Hers ( HIMS ) shares surged as much as 55% in pre-market trading on Monday morning after news that the company is creeping back into bed with Novo Nordisk ( NVO ). The excitementTech St ...

Core Insights - Hims & Hers Health Inc. has formed a significant partnership with Novo Nordisk to offer weight-loss medications, marking a strategic shift and enhancing its healthcare solutions portfolio [1][3] - The collaboration resolves a previous legal dispute and positions Hims & Hers to capitalize on the growing demand for accessible and affordable weight loss treatments in the U.S. [1][3] Partnership Details - The partnership allows Hims & Hers to provide U.S. customers access to FDA-approved GLP-1 treatments, including semaglutide injections and tablets, which are expected to impact the U.S. weight loss market significantly [2] - Hims & Hers will continue to offer compounded semaglutide on a limited basis and will cease promoting compounded GLP-1s in its marketing materials [3] Stock Performance - Following the announcement of the partnership, HIMS stock increased to $21.95, reflecting a 39.45% rise, with daily fluctuations between $20.99 and $23.51 [2] - The company's market capitalization is approximately $4.82 billion, with a trading volume of 109.37 million shares [2] Future Prospects - CEO Andrew Dudum expressed enthusiasm about the partnership, emphasizing the evolving U.S. weight loss landscape with more affordable, FDA-approved medications and flexible dosing options [3] - The collaboration positions Hims & Hers to enhance its competitive edge against other telehealth companies like Teladoc Health and Amwell [1]

Hims & Hers stock: why today's gains are unlikely to be sustainable# Hims & Hers stock: why today's gains are unlikely to be sustainableStock marketAuthorWajeeh KhanMar 09, 2026, 17:27 PM- The stock is still down some 38% versus its year-to-date high.- But Hims & Hers shares are unlikely to sustain these gains over time.- HIMS stock soars on a settlement and partnership with Novo Nordisk.Hims & Hers Health Inc (NYSE: HIMS) soared nearly 50% this morning after announcing a landmark settlement and partnership ...

Shares of Hims & Hers Health (NYSE: HIMS) skyrocketed after the telemedicine platform came to an agreement with Novo Nordisk (NYSE: NVO) to sell the drugmaker's popular GLP-1 weight loss drugs. The question on many investors' minds is whether it is too late to buy the stock. Let's take a closer look. Letting bygones be bygones Hims & Hers and Novo Nordisk have had a tumultuous relationship over the past couple of years. The companies formed a short-lived commercial partnership last year, only for Novo ...

News that a business is slashing prices isn't great if you're worried about its margins and overall profitability. But offering reduced prices can, however, help with winning market share. As a result, it's not always obvious whether a move to reduce prices can be beneficial for a stock in the long run. Pharmaceutical giant Novo Nordisk (NYSE: NVO) is planning to drastically reduce the list prices of its popular GLP-1 treatments, including Ozempic and Wegovy, next year. The company has been facing growin ...

Core Insights - Hims & Hers Health's stock price has surged following the announcement of a partnership with Novo Nordisk to sell GLP-1 weight-loss drugs, including Wegovy [1] - The partnership marks a significant turnaround in the relationship between Hims & Hers and Novo Nordisk, which was contentious just a month prior [1] Company Developments - Hims & Hers has confirmed the agreement with Novo Nordisk, indicating a strategic move to capitalize on the growing market for GLP-1 medications in the US [1] - Andrew Dudum, CEO of Hims & Hers, expressed optimism about the growth opportunities presented by the expanding range of branded GLP-1 medications [1] Market Reaction - The stock price increase of Hims & Hers reflects investor confidence in the potential success of the partnership with Novo Nordisk [1] - The announcement is expected to have a positive impact on Hims & Hers' market position and revenue streams [1]

整理 | GLP1减重宝典内容团队 在大多数人还沉浸在肥胖药市场纷争之际，一场围绕"降价药 vs 品牌药"的公开对峙悄然画上了句号——诺和诺德（Novo Nordisk）与远程医疗 平台Hims & Hers之间的纠纷突然反转，两家公司不仅终止了法律战，还计划重启合作，在Hims平台上共同销售旗下重磅药物，包括Wegovy和 Ozempic。 这起始于2025年的合作破裂与专利之争，是原研制药公司与新兴数字渠道之间商业利益博弈的生动注脚；它先是从蜜月合作转向法庭对峙，最 终又因共同利益而重新牵手，体现了医药市场在利益驱动下的"爱恨转向"。 ▍ 一拍即合：从合作到爆发的市场红利 时间回到2025年4月，诺和诺德与Hims首次签署合作协议，允许后者在其线上平台销售诺和诺德的明星减重药物Wegovy。对诺和诺德而言，这 一合作为其产品提供了更广泛的分发渠道；对Hims而言，获得正版药物授权则显著提升了平台信誉与市场渗透率，在减肥药热潮之下助推股价 上扬。 当时，Wegovy作为诺和诺德旗下重磅GLP‑1类减肥药，其高昂价格使许多患者望而却步，而Hims通过在线渠道提供医保外订购选择，填补了直 销与零售之外的一个重要 ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Core Insights - Hims & Hers Health announced a partnership with Novo Nordisk to sell the latter's weight-loss products, leading to a nearly 37% increase in Hims & Hers stock [1][1][1] - The partnership will allow Hims & Hers to offer Novo Nordisk's Ozempic and Wegovy through its platform later this month [1][1][1] - Novo Nordisk has dismissed its lawsuit against Hims & Hers regarding the sale of compounded medications, indicating renewed confidence in Hims [1][1][1] Company Developments - Hims & Hers previously launched its own compounded version of semaglutide, the active ingredient in Novo's Wegovy, which led to legal disputes with Novo Nordisk [1][1][1] - Despite the recent stock surge, Hims & Hers shares have lost approximately two-thirds of their value since their peak in February of the previous year [1][1][1] - Novo Nordisk's shares have decreased by about 50% over the past 12 months, reflecting broader challenges in the weight-loss drug market [1][1][1] Industry Context - The partnership comes at a time when the weight-loss drug industry is experiencing significant changes, with increased competition and regulatory scrutiny [1][1][1] - The deal may signal a shift in Novo Nordisk's approach to its U.S. GLP-1 business model, potentially impacting market dynamics [1][1][1]

Core Insights - Novo Nordisk (NVO) shares have dropped 22% in the past month, resulting in a loss of nearly $50 billion in market capitalization due to disappointing clinical developments and rising pricing pressures [2] - Eli Lilly (LLY) has emerged as a significant competitor in the GLP-1 obesity market, with its therapy Zepbound (tirzepatide) outperforming NVO's Wegovy in clinical trials [3][4] - Novo Nordisk plans to cut U.S. list prices for Wegovy, Ozempic, and Rybelsus to $675 per month starting January 2027 to enhance patient access, which may compress margins amid increasing competition [7] Competitive Landscape - Eli Lilly's Zepbound achieved 25.5% weight loss in a phase III study, surpassing Novo Nordisk's CagriSema, which recorded 23% weight loss, marking a competitive setback for NVO [4][5] - Lilly's oral GLP-1 candidate, orforglipron, has also outperformed Novo Nordisk's Rybelsus in a phase III study for type II diabetes, further strengthening Lilly's position in the market [6] Financial Performance - Novo Nordisk's stock has underperformed, losing 29.1% over the past six months compared to the industry's 20% growth [19] - The company's shares currently trade at a price/earnings ratio of 11.59, significantly lower than the industry average of 17.90, indicating a discount in valuation [22] Growth Outlook - Novo Nordisk's growth outlook is deteriorating due to slowing demand, rising costs, and limited near-term catalysts, with earnings estimates for 2026 and 2027 declining [8][24] - The company is expanding its portfolio beyond GLP-1 treatments, seeking approvals for therapies in rare diseases and liver care, including treatments for hemophilia and metabolic dysfunction-associated liver disease [15][16] Pipeline Developments - Novo Nordisk is advancing several next-generation obesity candidates, including CagriSema and amycretin, to strengthen its competitive position in the obesity market [17][18] - The company has also entered partnerships to develop oral small-molecule medicines for obesity and diabetes, indicating a strategic focus on expanding its treatment options [18]